On Monday, Century Therapeutics Inc (NASDAQ: IPSC) was 5.17% up from the session before settling in for the closing price of $0.56. A 52-week range for IPSC has been $0.52 – $4.78.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 27.56%. When this article was written, the company’s average yearly earnings per share was at 26.24%. With a float of $38.84 million, this company’s outstanding shares have now reached $85.84 million.
Let’s determine the extent of company efficiency that accounts for 150 employees. In terms of profitability, gross margin is -51.52%, operating margin of -2108.03%, and the pretax margin is -1893.43%.
Century Therapeutics Inc (IPSC) Breakdown of a Key Holders of the stock
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Century Therapeutics Inc stocks. The insider ownership of Century Therapeutics Inc is 54.86%, while institutional ownership is 34.94%. The most recent insider transaction that took place on Mar 10 ’25, was worth 1,375. In this transaction President and CEO of this company sold 2,235 shares at a rate of $0.61, taking the stock ownership to the 1,190,310 shares. Before that another transaction happened on Mar 10 ’25, when Company’s insider sold 2,360 for $0.61, making the entire transaction worth $1,451. This insider now owns 272,573 shares in total.
Century Therapeutics Inc (IPSC) Recent Fiscal highlights
According to the Wall Street analysts, stocks earnings will be around 26.24% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 6.80% during the next five years compared to 18.46% growth over the previous five years of trading.
Century Therapeutics Inc (NASDAQ: IPSC) Trading Performance Indicators
You can see what Century Therapeutics Inc (IPSC) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 1.50. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 7.62.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.62, a number that is poised to hit -0.07 in the next quarter and is forecasted to reach -1.30 in one year’s time.
Technical Analysis of Century Therapeutics Inc (IPSC)
Looking closely at Century Therapeutics Inc (NASDAQ: IPSC), its last 5-days average volume was 0.72 million, which is a jump from its year-to-date volume of 0.5 million. As of the previous 9 days, the stock’s Stochastic %D was 31.13%. Additionally, its Average True Range was 0.05.
During the past 100 days, Century Therapeutics Inc’s (IPSC) raw stochastic average was set at 4.70%, which indicates a significant decrease from 41.63% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 76.92% in the past 14 days, which was higher than the 74.06% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.7421, while its 200-day Moving Average is $1.5228. However, in the short run, Century Therapeutics Inc’s stock first resistance to watch stands at $0.5961. Second resistance stands at $0.6084. The third major resistance level sits at $0.6289. If the price goes on to break the first support level at $0.5633, it is likely to go to the next support level at $0.5428. Now, if the price goes above the second support level, the third support stands at $0.5305.
Century Therapeutics Inc (NASDAQ: IPSC) Key Stats
There are 86,045K outstanding shares of the company, which has a market capitalization of 50.22 million. As of now, sales total 2,240 K while income totals -136,670 K. Its latest quarter income was 790 K while its last quarter net income were -31,230 K.
